Being able to use minimal residual disease (MRD) negativity to make treatment decisions, such as stopping maintenance therapy, can have savings related to cost and quality of life (QOL) for patients, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
Being able to use minimal residual disease (MRD) negativity to make treatment decisions, such as stopping maintenance therapy, can have savings related to cost and quality of life for patients, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
Transcript
What elements of cancer care are covered in your evaluation of cost effectiveness? Do you consider drug costs only or other costs, such as infusion time?
We've looked at, what are the potential savings? If we devise an algorithm, if we devise a framework saying, “Somebody is on LEN [lenalidomide] maintenance for a 2-year-period, they achieved 2 consecutive MRD negativity values, a 10T, separated by almost a year or so, are these the right patients to stop maintenance?” So, the answer is yes. What would be the cost savings is what we looked at.
We made some assumptions. If somebody stops with sustained MRD negativity, they should have more MRD testings that are incorporated into their care every 3 months, including a bone marrow biopsy, including the patient visiting every 3 months, and so on. Whereas the control patient population, what we normally do: these patients don't go through those repeat, sequential MRD testing to look for that MRD negativity. What we do in this patient population is to continue giving them the standard of care of LEN maintenance, until progression. Using these 2 frameworks—the framework that I described about the discontinuation of the treatment—and comparing the cost savings over time is what we looked at.
It is clearly showing that in the long run, there's a huge significant savings, both from the cost and from the quality-of-life perspective, and a significant savings advantage if you're able to find that right recipe to identify those patients who would be able to stop off maintenance, because continuing the treatment comes with its baggage. It comes with adverse events; it comes with the declining quality of life. Those all could be prevented by doing this.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More